Sign inJoin waitlistJoin the waitlist

Kathryn Bylow

Section Chief · Medical College of Wisconsin Affiliated Hospitals, Inc

Credentials: · · · ·

History

University of Chicago Medical Center
2004–2007
Geriatric Medicine
University of Chicago Medical Center
2003–2004
Internal Medicine
Vanderbilt University Medical Center
2000–2003
University of Wisconsin School of Medicine and Public Health
1996–2000

Research

A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive…
Cancer · 2007 · 187 citations
Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy
Urology · 2008 · First of 8 authors · 114 citations
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review
Review · Cancer · 2007 · First of 4 authors · 98 citations

Walter Stadler
10 papers
Supriya Mohile
9 papers
WD
William Dale
9 papers
Deepak Kilari
5 papers
Miriam Rodin
4 papers
Daniel Petrylak
2 papers
John Burfeind
2 papers
Maureen Lacy
2 papers
Razelle Kurzrock
2 papers
Ruben Raychaudhuri
2 papers · 1 as a fellow
William Hall
2 papers
Adam Currey
1 paper

Clinical trials

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
Principal investigator · Completed · Phase 2
Medical College of Wisconsin
2014–2021
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2034
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2025–2034